AN2 Therapeutics, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by AN2 Therapeutics, Inc. (ANTX) on January 26, 2026. The filing discloses changes in the Company's executive leadership structure, specifically the appointment of a new Principal Accounting Officer and the amendment of the Chief Financial Officer's employment terms.
Key Financial Metrics
The filing does not provide financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on personnel changes and associated compensation adjustments.
Material Changes
- Appointment of Principal Accounting Officer: Sarah Williams was appointed Vice President, Controller, and Principal Accounting Officer, effective February 1, 2026. She succeeds Lucy Day in this specific role.
- Compensation Adjustment for Sarah Williams: Ms. Williams will receive an annual base salary of $310,000 with a target annual bonus of 30% of her base salary.
- Employment Amendment for Lucy Day: Ms. Day will continue as Chief Financial Officer and Principal Financial Officer. Her annual base salary is set at $335,400 through March 31, 2026, and will decrease to $223,600 effective April 1, 2026.
- Severance Terms for Lucy Day: Effective April 1, 2026, if Ms. Day is involuntarily terminated (not in connection with a change in control), she will be eligible for 50% of the severance benefits under the Officer Severance Plan.
Guidance, Outlook, and Risks
The filing does not contain forward-looking guidance, financial outlook, or specific risk factors. Management commentary is limited to the rationale for the changes, citing "cost-savings efforts" as a driver for the amended employment agreement with Ms. Day. No unusual items or contingencies were disclosed.
Key Facts for Investor Verification
- Verify the effective date of Sarah Williams' new role (February 1, 2026) and her prior tenure as Corporate Controller since May 2024.
- Confirm the specific reduction in Lucy Day's base salary from $335,400 to $223,600 effective April 1, 2026.
- Review the full text of the Amended and Restated Employment Letter Agreement with Ms. Day, which is expected to be filed as an exhibit to the Form 10-Q for the quarter ending March 31, 2026.
- Note that Ms. Day's outstanding equity awards will continue to vest while she remains employed.